share_log

Piper Sandler Maintains Neutral on Humacyte, Lowers Price Target to $3-Report Released on 9th Nov 2023

Benzinga ·  Nov 10, 2023 17:16

Piper Sandler analyst Matt O'Brien maintains Humacyte (NASDAQ:HUMA) with a Neutral and lowers the price target from $3.5 to $3.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment